CytoSorbents regains Nasdaq bid price compliance; MVLS delisting risk remains

Cytosorbents Corp

Regained compliance with Nasdaq Rule 5550(a)(2) after closing bid price held ≥$1.00 for 10 sessions ending Sept 21, 2026.
Still non-compliant with Rule 5550(b)(2) MVLS requirement: market value below $35M minimum; deadline Dec 28, 2026.
Company evaluating options, including raising stockholders' equity to at least $2.5M, to satisfy MVLS before deadline.
CEO reiterates priorities: operating cash flow breakeven in H2 2026, advancing DrugSorb-ATR toward FDA approval.
No assurance of regaining MVLS compliance or maintaining Nasdaq listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.